PMID- 34132690
OWN - NLM
STAT- MEDLINE
DCOM- 20220209
LR  - 20230911
IS  - 1533-4023 (Electronic)
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 78
IP  - 3
DP  - 2021 Sep 1
TI  - Effect of Canagliflozin Compared With Sitagliptin on Serum Lipids in Patients 
      with Type 2 Diabetes Mellitus and Heart Failure with Reduced Ejection Fraction: A 
      Post-Hoc Analysis of the CANA-HF Study.
PG  - 407-410
LID - 10.1097/FJC.0000000000001083 [doi]
AB  - The sodium glucose co-transporter 2 inhibitors have demonstrated favorable 
      effects on cardiovascular and renal disease; however, they may also increase 
      low-density lipoprotein cholesterol (LDL-C). There are limited data directly 
      comparing the effects of sodium glucose co-transporter 2inhibitors on serum 
      lipids to other antihyperglycemic therapies. In this post-hoc analysis of the 
      CANA-HF trial, we sought to compare the effects of canagliflozin to sitagliptin 
      in patients with type 2 diabetes mellitus (T2DM) and heart failure and reduced 
      ejection fraction (HFrEF). The CANA-HF trial was a prospective, randomized 
      controlled study that compared the effects of canagliflozin 100 mg daily to 
      sitagliptin 100 mg daily on cardiorespiratory fitness in patients with HFrEF and 
      T2DM. Of the 36 patients enrolled in CANA-HF, 35 patients had both baseline and 
      12-weeks serum lipids obtained via venipuncture. The change in LDL-C from 
      baseline to 12 weeks was 5 (-12.5 to 19.5) mg/dL versus -8 (-19 to -1) mg/dL (P = 
      0.82) and triglyceride levels was -4 (-26 to 9) mg/dL and -10.5 (-50 to 29.3) 
      mg/dL (P = 0.52) for canagliflozin and sitagliptin, respectively. No significant 
      differences were found between canagliflozin and sitagliptin for total 
      cholesterol, high-density lipoprotein cholesterol or non-HDL-C (P > 0.5 for all). 
      These data suggest that compared with sitagliptin, canagliflozin may not increase 
      LDL-C in patients with T2DM and HFrEF.
CI  - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Dixon, Dave L
AU  - Dixon DL
AUID- ORCID: 0000-0001-7560-9521
AD  - Virginia Commonwealth University School of Pharmacy, Richmond, VA.
AD  - Virginia Commonwealth University Pauley Heart Center, Richmond, VA.
FAU - Billingsley, Hayley E
AU  - Billingsley HE
AD  - Virginia Commonwealth University Pauley Heart Center, Richmond, VA.
AD  - Department of Kinesiology and Health Sciences Virginia Commonwealth University 
      College of Humanities and Science, Richmond, VA; and.
FAU - Canada, Justin M
AU  - Canada JM
AD  - Virginia Commonwealth University Pauley Heart Center, Richmond, VA.
FAU - Trankle, Cory R
AU  - Trankle CR
AD  - Virginia Commonwealth University Pauley Heart Center, Richmond, VA.
FAU - Kadariya, Dinesh
AU  - Kadariya D
AD  - Virginia Commonwealth University Pauley Heart Center, Richmond, VA.
FAU - Cooke, Richard
AU  - Cooke R
AD  - Virginia Commonwealth University Pauley Heart Center, Richmond, VA.
FAU - Hart, Linda
AU  - Hart L
AD  - Bon Secours Heart and Vascular Institute, Richmond, VA.
FAU - Van Tassell, Benjamin
AU  - Van Tassell B
AD  - Virginia Commonwealth University School of Pharmacy, Richmond, VA.
AD  - Virginia Commonwealth University Pauley Heart Center, Richmond, VA.
FAU - Abbate, Antonio
AU  - Abbate A
AD  - Virginia Commonwealth University Pauley Heart Center, Richmond, VA.
FAU - Carbone, Salvatore
AU  - Carbone S
AD  - Virginia Commonwealth University Pauley Heart Center, Richmond, VA.
AD  - Bon Secours Heart and Vascular Institute, Richmond, VA.
LA  - eng
GR  - UL1 TR002649/TR/NCATS NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Biomarkers)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0SAC974Z85 (Canagliflozin)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
SB  - IM
MH  - Biomarkers/blood
MH  - Canagliflozin/adverse effects/*therapeutic use
MH  - Cholesterol/*blood
MH  - Cholesterol, HDL/blood
MH  - Cholesterol, LDL/blood
MH  - Diabetes Mellitus, Type 2/blood/diagnosis/*drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Heart Failure, Systolic/blood/diagnosis/*drug therapy/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Sitagliptin Phosphate/adverse effects/*therapeutic use
MH  - Sodium-Glucose Transporter 2 Inhibitors/adverse effects/*therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC8711068
MID - NIHMS1765439
COIS- A. Abbate has served as consultant to Janssen. S. Carbone is supported by a 
      Career Development Award 19CDA34660318 from the American Heart Association and by 
      the Clinical and Translational Science Awards Program UL1TR002649 from National 
      Institutes of Health to Virginia Commonwealth University. The remaining authors 
      reports no conflicts of interest.
EDAT- 2021/06/17 06:00
MHDA- 2022/02/10 06:00
PMCR- 2022/09/01
CRDT- 2021/06/16 12:20
PHST- 2021/04/10 00:00 [received]
PHST- 2021/05/12 00:00 [accepted]
PHST- 2021/06/17 06:00 [pubmed]
PHST- 2022/02/10 06:00 [medline]
PHST- 2021/06/16 12:20 [entrez]
PHST- 2022/09/01 00:00 [pmc-release]
AID - 00005344-202109000-00011 [pii]
AID - 10.1097/FJC.0000000000001083 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 2021 Sep 1;78(3):407-410. doi: 
      10.1097/FJC.0000000000001083.